Tactile Systems Technology (TCMD)
Market Price (2/3/2026): $28.735 | Market Cap: $641.3 MilSector: Health Care | Industry: Life Sciences Tools & Services
Tactile Systems Technology (TCMD)
Market Price (2/3/2026): $28.735Market Cap: $641.3 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 24x, P/EPrice/Earnings or Price/(Net Income) is 35x |
| Attractive yieldFCF Yield is 6.1% | Stock price has recently run up significantly6M Rtn6 month market price return is 190% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, Aging Population & Chronic Disease, and Precision Medicine. Themes include Remote Patient Monitoring, Show more. | Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 92% |
| Key risksTCMD key risks include [1] regulatory scrutiny and audits of its billing practices, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13% |
| Attractive yieldFCF Yield is 6.1% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, Aging Population & Chronic Disease, and Precision Medicine. Themes include Remote Patient Monitoring, Show more. |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 24x, P/EPrice/Earnings or Price/(Net Income) is 35x |
| Stock price has recently run up significantly6M Rtn6 month market price return is 190% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 92% |
| Key risksTCMD key risks include [1] regulatory scrutiny and audits of its billing practices, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Tactile Systems Technology reported strong third-quarter 2025 financial results, exceeding both EPS and revenue estimates, and subsequently raised its full-year 2025 revenue guidance. This robust financial performance signaled underlying business strength and improved investor confidence.
2. The company announced a US$25 million share repurchase program following its positive Q3 2025 earnings report. This initiative demonstrated management's confidence in the company's valuation and commitment to returning value to shareholders, further boosting the stock price.
Show more
Stock Movement Drivers
Fundamental Drivers
The 90.6% change in TCMD stock from 10/31/2025 to 2/2/2026 was primarily driven by a 53.3% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 2022026 | Change |
|---|---|---|---|
| Stock Price ($) | 15.07 | 28.73 | 90.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 299 | 312 | 4.2% |
| Net Income Margin (%) | 5.1% | 5.8% | 15.3% |
| P/E Multiple | 23.0 | 35.3 | 53.3% |
| Shares Outstanding (Mil) | 23 | 22 | 3.5% |
| Cumulative Contribution | 90.6% |
Market Drivers
10/31/2025 to 2/2/2026| Return | Correlation | |
|---|---|---|
| TCMD | 90.6% | |
| Market (SPY) | 2.0% | -7.2% |
| Sector (XLV) | 7.9% | 10.6% |
Fundamental Drivers
The 187.9% change in TCMD stock from 7/31/2025 to 2/2/2026 was primarily driven by a 141.5% change in the company's P/E Multiple.| (LTM values as of) | 7312025 | 2022026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.98 | 28.73 | 187.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 293 | 312 | 6.3% |
| Net Income Margin (%) | 5.5% | 5.8% | 5.6% |
| P/E Multiple | 14.6 | 35.3 | 141.5% |
| Shares Outstanding (Mil) | 24 | 22 | 6.2% |
| Cumulative Contribution | 187.9% |
Market Drivers
7/31/2025 to 2/2/2026| Return | Correlation | |
|---|---|---|
| TCMD | 187.9% | |
| Market (SPY) | 10.3% | -1.7% |
| Sector (XLV) | 19.9% | 12.0% |
Fundamental Drivers
The 64.1% change in TCMD stock from 1/31/2025 to 2/2/2026 was primarily driven by a 29.8% change in the company's P/E Multiple.| (LTM values as of) | 1312025 | 2022026 | Change |
|---|---|---|---|
| Stock Price ($) | 17.51 | 28.73 | 64.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 285 | 312 | 9.3% |
| Net Income Margin (%) | 5.4% | 5.8% | 7.6% |
| P/E Multiple | 27.2 | 35.3 | 29.8% |
| Shares Outstanding (Mil) | 24 | 22 | 7.5% |
| Cumulative Contribution | 64.1% |
Market Drivers
1/31/2025 to 2/2/2026| Return | Correlation | |
|---|---|---|
| TCMD | 64.1% | |
| Market (SPY) | 16.6% | 16.1% |
| Sector (XLV) | 7.4% | 25.9% |
Fundamental Drivers
The 121.5% change in TCMD stock from 1/31/2023 to 2/2/2026 was primarily driven by a 84.9% change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2022026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.97 | 28.73 | 121.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 235 | 312 | 32.8% |
| P/S Multiple | 1.1 | 2.1 | 84.9% |
| Shares Outstanding (Mil) | 20 | 22 | -9.8% |
| Cumulative Contribution | 121.5% |
Market Drivers
1/31/2023 to 2/2/2026| Return | Correlation | |
|---|---|---|
| TCMD | 121.5% | |
| Market (SPY) | 77.5% | 21.4% |
| Sector (XLV) | 22.2% | 23.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| TCMD Return | -58% | -40% | 25% | 20% | 69% | -0% | -36% |
| Peers Return | 9% | -19% | 3% | 39% | -26% | 4% | -3% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 85% |
Monthly Win Rates [3] | |||||||
| TCMD Win Rate | 25% | 42% | 67% | 58% | 67% | 0% | |
| Peers Win Rate | 53% | 42% | 52% | 57% | 40% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| TCMD Max Drawdown | -58% | -66% | -13% | -22% | -45% | -6% | |
| Peers Max Drawdown | -16% | -40% | -23% | -17% | -38% | -6% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ELMD, ENOV, ITGR, AVNS, MASI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/2/2026 (YTD)
How Low Can It Go
| Event | TCMD | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -89.5% | -25.4% |
| % Gain to Breakeven | 853.9% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -55.7% | -33.9% |
| % Gain to Breakeven | 125.8% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -45.7% | -19.8% |
| % Gain to Breakeven | 84.3% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to ELMD, ENOV, ITGR, AVNS, MASI
In The Past
Tactile Systems Technology's stock fell -89.5% during the 2022 Inflation Shock from a high on 2/12/2021. A -89.5% loss requires a 853.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Tactile Systems Technology (TCMD)
AI Analysis | Feedback
'ResMed for lymphedema treatment'
'Insulet (Omnipod) for chronic swelling management'
AI Analysis | Feedback
- Flexitouch Plus System: An advanced pneumatic compression device used for at-home treatment of lymphedema and chronic venous insufficiency.
- Entre System: A basic pneumatic compression device designed for the management and treatment of lymphedema.
- AffloVest: A portable high-frequency chest wall oscillation (HFCWO) therapy device used for airway clearance in patients with respiratory conditions.
AI Analysis | Feedback
Tactile Systems Technology (TCMD) - Major Customers
Tactile Systems Technology (TCMD) primarily sells its medical devices, such as the Flexitouch Plus system, directly to individual patients who have received a prescription from their healthcare providers. Therefore, its major customers can be categorized by the medical conditions they treat:
- Patients suffering from Lymphedema: This includes individuals with primary lymphedema (due to hereditary factors) and secondary lymphedema (often resulting from cancer treatment, surgery, or trauma) affecting various body parts.
- Patients suffering from Chronic Venous Insufficiency (CVI): Specifically, those with advanced stages of CVI who experience symptoms like leg swelling, pain, and skin changes, and are prescribed pneumatic compression therapy to manage their condition.
AI Analysis | Feedback
nullAI Analysis | Feedback
Sheri L. Dodd, Chief Executive Officer
Ms. Sheri L. Dodd has served as the Director and Chief Executive Officer of Tactile Systems Technology since July 2024. Her career in the healthcare industry spans nearly 30 years, encompassing global pharmaceutical, medical device, and digital health sectors. Before joining Tactile Medical, she was the President of Medtronic Canada. She also led Medtronic's Care Management Services business, which focused on caring for complex patients at home, and managed Medtronic's non-intensive diabetes therapy business. Her experience also includes senior roles at Medtronic plc, where she oversaw commercial and clinical functions, and Johnson & Johnson, where she worked on health economics and reimbursement strategies. Additionally, Ms. Dodd contributed to global health initiatives during her time with the World Health Organization. She became a member of Tactile's Board of Directors in January 2021.
Elaine Birkemeyer, Chief Financial Officer
Ms. Elaine Birkemeyer has been the Chief Financial Officer of Tactile Systems Technology since March 2023. She brings over 25 years of experience in finance, accounting, and business strategy, with significant senior leadership roles in large divisions within the healthcare, consumer, and retail industries, including multiple Fortune 500 companies. Prior to her role at Tactile Medical, she served as Chief Financial Officer of Rally Health, a digital health company wholly owned by UnitedHealth Group. She also held the position of Chief Financial Officer for UnitedHealth's Care Solutions portfolio. Her experience at UnitedHealth Group also includes leading finance for its Optum Operations business as Vice President and later Senior Vice President. Earlier in her career, Ms. Birkemeyer was a Senior Finance Manager for Sleep Number Corporation and held various roles of increasing responsibility at Target Corporation.
William W. Burke, Chairman Executive Board
Mr. William W. Burke has served as the Chairman of Tactile Systems Technology since 2015. His previous roles include serving as the President of Austin Highlands Advisors LLC. He also served as a Member of the Board of Directors at Invuity Inc. Currently, he is a Member of the Board of Directors at Nalu Medical Inc and Ceribell.
David J. Kaercher, Chief Information Officer
Mr. David J. Kaercher is the Chief Information Officer of Tactile Systems Technology. His prior experience includes serving as Chief Information Officer for multiple Blue Cross and Blue Shield plans. He was also the Senior Vice President for US Bank Technology and Operations Services (TOS) and Vice President of Allianz Life Technology. Additionally, Mr. Kaercher worked as a Director for Best Buy Technology and as a Manager/Consultant for IBM.
Antonios P. Gasparis, MD, Chief Medical Officer
Dr. Antonios P. Gasparis has been the Chief Medical Officer of Tactile Systems Technology since 2023. Before joining the company, he served as the System Chief, Venous Disease of Northwell Health. He also held the position of Director of Stony Brook Vein Center at Stony Brook University Medical Center.
AI Analysis | Feedback
The key risks to Tactile Systems Technology (TCMD) are:
- Reimbursement Challenges and Regulatory Scrutiny: Tactile Systems Technology heavily relies on reimbursement from third-party payers, including Medicare, Veterans Administration, and private insurers, for its medical devices. Any changes in reimbursement policies, such as stricter documentation requirements, denials of claims, or adverse coverage decisions, can significantly impact the company's revenue and financial performance. The company has also faced and continues to be susceptible to regulatory issues, including audits and investigations into billing practices.
- Intense Competition and Market Dependence: The company operates in a competitive market for pneumatic compression devices, facing established players like Bio Compression Systems and Lympha Press, as well as emerging companies. A significant portion of Tactile Systems Technology's revenue is driven by its flagship product, Flexitouch Plus, making it highly dependent on the continued success and demand for this core product. Increased competition or a decline in demand for its key products could negatively affect its market share and financial results.
- Legal and Compliance Issues: Tactile Systems Technology has encountered legal challenges, including "qui tam" actions alleging violations of the Federal False Claims Act and Anti-Kickback Statute. Such allegations, regardless of their merit, can lead to costly litigation, diversion of management's attention, potential fines, and damage to the company's reputation and financial health.
AI Analysis | Feedback
nullAI Analysis | Feedback
Tactile Systems Technology (TCMD) primarily focuses on developing and providing medical devices for the treatment of chronic conditions such as lymphedema, chronic venous insufficiency (CVI), and bronchiectasis. The company's main products include the Flexitouch Plus System for lymphedema, the Entre Plus System for venous disorders, and the AffloVest for airway clearance in bronchiectasis patients.
- The combined addressable market opportunity for lymphedema and bronchiectasis is estimated at $10 billion in the U.S..
- Specifically, the lymphedema treatment market in the U.S. is projected to grow from $0.95 billion in 2025 to $1.46 billion by 2030.
AI Analysis | Feedback
Tactile Systems Technology (TCMD) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends:
- Continued Strong Growth in Airway Clearance Products: The company's airway clearance products, particularly the AffloVest system, have demonstrated significant year-over-year revenue growth. For example, in Q3 2025, revenue from airway clearance products increased by 71% year-over-year. Tactile Systems Technology anticipates growth for its airway clearance product line to be between 52% and 55% for the full year 2025, driven by increased durable medical equipment (DME) partnerships and market awareness.
- Lymphedema Product Line Momentum and Nimbl Platform Expansion: While growth in the lymphedema segment has been more modest, the company is seeing recovery and expects continued improvement. Sales and rentals of lymphedema products, including the Flexitouch, Entrée, and Nimbl systems, increased by 11% year-over-year in Q3 2025. The expanded launch of the Nimbl platform to include patients with lower extremity conditions, which represents the largest segment of the lymphedema market, is a significant driver. Management expects lymphedema revenue growth to be 3% to 4% for the full year 2025.
- Sales Force Expansion and Enhanced Productivity: Tactile Systems Technology is investing in and optimizing its sales organization. This includes increasing its sales headcount to the largest field presence in its history (329 representatives as of Q3 2025) and implementing new customer relationship management (CRM) tools and data-driven sales management strategies. These initiatives are expected to boost sales force productivity and more efficiently reach lymphedema patients, with returns from these investments materializing over multiple years.
- Favorable Medicare Policy Shift: A significant driver for future growth in the lymphedema market is the favorable Medicare policy shift from Local Coverage Determinations (LCD) to a National Coverage Determination (NCD) for lymphedema pneumatic compression devices. This change is expected to expand access to advanced pump therapy for patients, driving further improvement into Q4 2025 and 2026.
- Product Innovation and Portfolio Development: The company continues to focus on product innovation. This includes the submission of a 510(k) for a next-generation AffloVest system, which is expected to offer reduced weight, improved connectivity, and a better fit. Additionally, the strategic buildup of its patent portfolio around proprietary pneumatic compression technologies positions Tactile Systems Technology to capture disproportionate market share in the expanding lymphedema treatment market.
AI Analysis | Feedback
Share Repurchases
- On November 3, 2025, Tactile Systems Technology authorized a new share repurchase program for up to $25 million of its common stock.
- The share repurchase program is effective from November 3, 2025, and is set to expire on November 3, 2027.
- The company anticipates funding the repurchases through its existing cash reserves and future cash flows.
Capital Expenditures
- In the last 12 months, Tactile Systems Technology reported capital expenditures of -$2.33 million.
- Projected capital expenditures are $3 million for 2025, $3 million for 2026, and $4 million for 2027.
- These capital expenditures are estimated to represent approximately 1% of the company's revenue annually from 2025 through 2029.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Tactile Systems Technology Earnings Notes | 12/16/2025 | |
| Tactile Systems Technology Stock Jump Looks Great, But How Secure Is That Gain? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 29.45 |
| Mkt Cap | 1.0 |
| Rev LTM | 1,265 |
| Op Inc LTM | 27 |
| FCF LTM | 57 |
| FCF 3Y Avg | 41 |
| CFO LTM | 154 |
| CFO 3Y Avg | 92 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.6% |
| Rev Chg 3Y Avg | 11.5% |
| Rev Chg Q | 8.5% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 6.8% |
| Op Mgn 3Y Avg | 7.7% |
| QoQ Delta Op Mgn LTM | 0.8% |
| CFO/Rev LTM | 12.3% |
| CFO/Rev 3Y Avg | 10.9% |
| FCF/Rev LTM | 9.2% |
| FCF/Rev 3Y Avg | 6.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.0 |
| P/S | 1.8 |
| P/EBIT | 9.0 |
| P/E | 14.8 |
| P/CFO | 15.0 |
| Total Yield | -2.4% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 2.9% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 9.4% |
| 3M Rtn | 22.9% |
| 6M Rtn | 2.8% |
| 12M Rtn | -21.2% |
| 3Y Rtn | -1.0% |
| 1M Excs Rtn | 3.1% |
| 3M Excs Rtn | 20.7% |
| 6M Excs Rtn | -5.5% |
| 12M Excs Rtn | -38.2% |
| 3Y Excs Rtn | -71.6% |
Price Behavior
| Market Price | $28.73 | |
| Market Cap ($ Bil) | 0.6 | |
| First Trading Date | 07/28/2016 | |
| Distance from 52W High | -6.5% | |
| 50 Days | 200 Days | |
| DMA Price | $28.47 | $16.89 |
| DMA Trend | up | up |
| Distance from DMA | 0.9% | 70.1% |
| 3M | 1YR | |
| Volatility | 92.3% | 68.8% |
| Downside Capture | -171.21 | 44.52 |
| Upside Capture | 192.59 | 88.18 |
| Correlation (SPY) | -6.7% | 16.3% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.15 | 0.71 | -0.57 | -0.24 | 0.58 | 0.80 |
| Up Beta | 5.94 | 2.14 | 0.43 | 0.99 | 0.59 | 0.81 |
| Down Beta | 0.68 | 0.82 | -2.22 | -0.61 | 0.52 | 0.80 |
| Up Capture | 14% | 111% | 251% | 148% | 87% | 72% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 9 | 21 | 30 | 68 | 124 | 375 |
| Down Capture | 34% | -57% | -210% | -319% | 60% | 91% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 11 | 20 | 31 | 55 | 121 | 366 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TCMD | |
|---|---|---|---|---|
| TCMD | 64.5% | 68.7% | 0.99 | - |
| Sector ETF (XLV) | 7.1% | 17.2% | 0.24 | 25.8% |
| Equity (SPY) | 16.0% | 19.2% | 0.64 | 16.1% |
| Gold (GLD) | 66.9% | 23.7% | 2.11 | -9.5% |
| Commodities (DBC) | 7.0% | 16.3% | 0.23 | -6.3% |
| Real Estate (VNQ) | 2.9% | 16.5% | -0.00 | 23.7% |
| Bitcoin (BTCUSD) | -19.7% | 39.9% | -0.46 | 3.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TCMD | |
|---|---|---|---|---|
| TCMD | -11.7% | 59.9% | 0.03 | - |
| Sector ETF (XLV) | 7.3% | 14.5% | 0.33 | 27.1% |
| Equity (SPY) | 14.1% | 17.1% | 0.66 | 29.8% |
| Gold (GLD) | 19.9% | 16.6% | 0.97 | 1.5% |
| Commodities (DBC) | 11.4% | 18.9% | 0.49 | -0.7% |
| Real Estate (VNQ) | 4.5% | 18.8% | 0.15 | 28.8% |
| Bitcoin (BTCUSD) | 20.9% | 57.6% | 0.56 | 13.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TCMD | |
|---|---|---|---|---|
| TCMD | 10.3% | 56.7% | 0.42 | - |
| Sector ETF (XLV) | 10.6% | 16.6% | 0.53 | 31.1% |
| Equity (SPY) | 15.9% | 17.9% | 0.76 | 33.4% |
| Gold (GLD) | 15.0% | 15.3% | 0.81 | 0.6% |
| Commodities (DBC) | 8.3% | 17.6% | 0.39 | 6.7% |
| Real Estate (VNQ) | 5.8% | 20.8% | 0.25 | 29.6% |
| Bitcoin (BTCUSD) | 71.1% | 66.4% | 1.10 | 8.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/3/2025 | 40.6% | 57.8% | 70.0% |
| 8/4/2025 | 26.8% | 23.1% | 33.9% |
| 5/5/2025 | -29.0% | -30.3% | -27.3% |
| 2/18/2025 | -13.3% | -18.1% | -22.8% |
| 11/4/2024 | -11.1% | 5.6% | 25.9% |
| 8/5/2024 | 13.9% | 12.4% | 15.2% |
| 5/6/2024 | 1.8% | -2.5% | -14.7% |
| 2/20/2024 | -3.2% | 5.8% | 9.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 12 | 13 |
| # Negative | 12 | 10 | 9 |
| Median Positive | 14.0% | 11.3% | 15.2% |
| Median Negative | -12.0% | -12.6% | -14.2% |
| Max Positive | 40.6% | 57.8% | 70.0% |
| Max Negative | -29.0% | -30.3% | -44.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/03/2025 | 10-Q |
| 06/30/2025 | 08/04/2025 | 10-Q |
| 03/31/2025 | 05/05/2025 | 10-Q |
| 12/31/2024 | 02/18/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/05/2024 | 10-Q |
| 03/31/2024 | 05/06/2024 | 10-Q |
| 12/31/2023 | 02/20/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 02/21/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| 06/30/2022 | 08/01/2022 | 10-Q |
| 03/31/2022 | 05/02/2022 | 10-Q |
| 12/31/2021 | 02/23/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Burns, Kristie | Sr. VP Mktg & Clinical Affairs | Direct | Sell | 1062026 | 28.85 | 5,139 | 148,260 | 2,088,769 | Form |
| 2 | Dodd, Sheri Louise | Chief Executive Officer | Direct | Sell | 8122025 | 12.36 | 7,762 | 95,907 | 2,143,507 | Form |
| 3 | Birkemeyer, Elaine M | Chief Financial Officer | Direct | Sell | 5142025 | 9.94 | 2,921 | 29,037 | 985,253 | Form |
| 4 | Dodd, Sheri Louise | Chief Executive Officer | Direct | Sell | 5122025 | 9.83 | 3,149 | 30,955 | 1,781,599 | Form |
| 5 | Burke, William W | Direct | Sell | 5092025 | 9.67 | 3,300 | 31,911 | 469,188 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.